Your browser doesn't support javascript.
loading
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters, S; Felip, E; Dafni, U; Belka, C; Guckenberger, M; Irigoyen, A; Nadal, E; Becker, A; Vees, H; Pless, M; Martinez-Marti, A; Tufman, A; Lambrecht, M; Andratschke, N; Piguet, A C; Kassapian, M; Roschitzki-Voser, H; Rabaglio-Poretti, M; Stahel, R A; Vansteenkiste, J; De Ruysscher, D.
Affiliation
  • Peters S; Centre Hospitalier Universitaire Vaudois (CHUV), Département d'Oncologie, Lausanne, Switzerland.
  • Felip E; Vall d'Hebron University Hospital, Institute of Oncology (VHIO), Barcelona, Spain.
  • Dafni U; Frontier Science Foundation-Hellas & National and Kapodistrian University of Athens, Greece.
  • Belka C; Department of Radiation Oncology and DZL Munich, University Hospital, LMU Munich, Germany.
  • Guckenberger M; University Hospital Zurich, Department for Radiation Oncology, University of Zurich, Switzerland.
  • Irigoyen A; Hospital Virgen De La Salud, Department of Medical Oncology, Toledo, Spain.
  • Nadal E; Catalan Institute of Oncology, Department of Medical Oncology, IDIBELL L'Hospitalet, Barcelona, Spain.
  • Becker A; Amsterdam University Medical Center, Department of Respiratory Diseases, Amsterdam, the Netherlands.
  • Vees H; Clinic Hirslanden, Radiation Oncology, Zürich, Switzerland.
  • Pless M; Cantonal Hospital Winterthur, Medical Oncology, Winterthur, Switzerland.
  • Martinez-Marti A; Vall d'Hebron University Hospital, Institute of Oncology (VHIO), Barcelona, Spain.
  • Tufman A; Ludwig Maximilian University of Munich (LMU), Medizinische Klinik and Poliklinik V, German Center for Lung Research, Munich, Germany.
  • Lambrecht M; University Hospitals Gasthuisberg, Department of Radiotherapy-Oncology, Leuven, Belgium.
  • Andratschke N; University Hospital Zurich, Department for Radiation Oncology, University of Zurich, Switzerland.
  • Piguet AC; European Thoracic Oncology Platform (ETOP), Bern, Switzerland.
  • Kassapian M; Frontier Science Foundation-Hellas, Athens, Greece.
  • Roschitzki-Voser H; European Thoracic Oncology Platform (ETOP), Bern, Switzerland.
  • Rabaglio-Poretti M; European Thoracic Oncology Platform (ETOP), Bern, Switzerland.
  • Stahel RA; University Hospital Zurich, Department of Haematology and Oncology, Switzerland.
  • Vansteenkiste J; University Hospitals Gasthuisberg, Department of Respiratory Diseases, Leuven, Belgium.
  • De Ruysscher D; Maastro Clinic, Department of Radiation Oncology Maastricht, the Netherlands. Electronic address: dirk.deruysscher@maastro.nl.
Lung Cancer ; 133: 83-87, 2019 07.
Article in En | MEDLINE | ID: mdl-31200833
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Platinum Compounds / Carcinoma, Non-Small-Cell Lung / Nivolumab / Lung Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2019 Document type: Article Affiliation country: Suiza Country of publication: Irlanda
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Platinum Compounds / Carcinoma, Non-Small-Cell Lung / Nivolumab / Lung Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2019 Document type: Article Affiliation country: Suiza Country of publication: Irlanda